rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Dean J. Mitchell

Director

Company insider

Files Form 4 as: Director, Theravance Biopharma; Director, Praxis Precision Medicines; Director, Kinnate Biopharma; Director and 10% owner, Precigen; Director, ImmunoGen; Director, Ista Pharmaceuticals; Director, Talecris Biotherapeutics Holdings; President and CEO, Alpharma.

Every Form 4 they filed

In numbers

Trades disclosed
297
Buys
7
Sells
5
Bought
$592K
Sold
$2.1M
Companies
9
Companies where not an officer
8
First trade
3 Oct 2005
Last trade
23 Sep 2026
Last filed
24 Sep 2026

Companies traded

Where they are an officer
AlpharmaDirector, Officer · last 29 Dec 20082 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
Theravance BiopharmaDirector · Pharmaceuticals · last 23 Sep 20260 buys · 0 sells
PRAX Praxis Precision MedicinesDirector · Biotechnology · last 10 Jun 20262 buys · 0 sells
Kinnate BiopharmaDirector · last 3 Apr 20240 buys · 0 sells
PGEN PrecigenDirector, 10% owner · Biotechnology · last 14 Mar 20242 buys · 0 sells
ImmunoGenDirector · last 12 Feb 20241 buy · 0 sells
Ista PharmaceuticalsDirector · last 6 Jun 20120 buys · 0 sells
Talecris Biotherapeutics HoldingsDirector · last 1 Jun 20110 buys · 0 sells
Mgi PharmaDirector · last 28 Jan 20080 buys · 5 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
23 Sep 2026filed 24 Sep 2026Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code D—91,204filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—24,258filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—13,398filing
23 Sep 2026filed 24 Sep 2026Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code D—6,009filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—6,000filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—6,000filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—6,000filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—6,000filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—6,000filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—28,000filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—22,044filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—23,576filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—24,258filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—13,398filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—6,000filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—6,000filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—6,000filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—28,000filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—22,044filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—23,576filing

Sectors

Health Care4
Not placed8

Buys in green, sells in red, by the company’s sector.

Related people

Gilbert Ray Cisneros, Jr.Representative, CA-31 · Also traded PRAX in the last 90 days
Jeffrey B. KindlerDirector · Also traded PGEN in the last 90 days
Phil TennantChief Commercial Officer · Also traded PGEN in the last 90 days
Rutul R. ShahChief Operating Officer · Also traded PGEN in the last 90 days
Nancy H. AgeeDirector · Also traded PGEN in the last 90 days
Harry Thomasian Jr.Chief Financial Officer · Also traded PGEN in the last 90 days